WEKO3
アイテム
Assessment of PERCIST criteria of FDG-PET/CT to predict progression-free survival after carbon-ion radiotherapy in patients with locally advanced pancreas cancer.
https://repo.qst.go.jp/records/74785
https://repo.qst.go.jp/records/747858f292de0-1651-45bc-9a1e-131cc7a8d52b
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-03-14 | |||||
| タイトル | ||||||
| タイトル | Assessment of PERCIST criteria of FDG-PET/CT to predict progression-free survival after carbon-ion radiotherapy in patients with locally advanced pancreas cancer. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Nishii, Ryuichi
× Nishii, Ryuichi× Higashi, Tatsuya× Yamada, Shigeru× Isozaki, Yuka× Kawashiro, Shohei× Yoshinaga, Keiichiro× Kamada, Tadashi× Nishii, Ryuichi× Higashi, Tatsuya× Yamada, Shigeru× Isozaki, Yuka× Kawashiro, Shohei× Yoshinaga, Keiichiro× Kamada, Tadashi |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | [Objective] FDG-PET/CT has been reported to be of prognostic value for pancreaic cancer. However, few previos studies have shown the relationsip between FDG-PET/CT metabolic parameters and the early response after carbon-ion radiotherapy (CIRT) and surgeryain patients with pancreatic cancer. The aim of this study is to assess the metabolic changes on F-18 FDG-PET/CT (FDG-PET/CT ) performed before and 3 months after CIRT in patients with locally advanced pancreatic cancer. [Materials and Methods] Nineteen locally advanced pancreatic cancer patients who had pre-CIRT chemotherapy followed by 55.2Gy/12Fractions CIRT were enrolled in this study. Patients received FDG-PET/CT before treatment (pre-CIRT PET/CT) and 3 months from the end of CIRT (3M-CIRT PET/CT)metabolic parameters such as SUVmax, Metabolic tumor volume (MTV), Total lesion glyclysis and SUVpeak were evaluated to assess the relationship with the early response of CIRT for the pancreatic cancer. Moreover, On 3M-CIRT PET/CT, metabolic response group of CMR or PMR was defined as responder, and another group of SMD or PMD was defined as non-responder. Then, PERCIRT were used for response evaluation based on SUV corrected for lean body mass (SUL and SULpeak). [Rsults] SUVmax pre- and 3M after CIRT were 4.32+/-1.50 and 2.94+/-0.83, respectively. MTV pre- and 3M after CIRT were 4.45+/-3.78 and 2.34+/-2.44, respectively. TLG pre- and 3M after CIRT were 17.39+/-17.39 and 6.89+/-8.33, respectively. SUVpeak pre- and 3M after CIRT were 3.94+/-1.39 and 2.64+/-0.96, respectively. Lof-rank t-test analysis for progression free survival revealed that patients who showed SUVpeak-reduction greater than 30% than that of pre-CIRT predicted early response of the therapy. The result of Kaplan-Meier analysis of PFS stratified using PERCIST showed a significant difference getween responder group and non-responder group (P<0.05, Lof-rand test). [Conclusion] The chanses of metabolic activity ana PERCIST criteria based of FDG-PET/CT during pre and 3 months after CIRT would be useful for prediction of progression-free survival after CIRT in patients with locally advanced pancreatic cancer. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | SNMMI2018 | |||||
| 発表年月日 | ||||||
| 日付 | 2018-06-25 | |||||
| 日付タイプ | Issued | |||||
